Table 3.
Genes with promoter region DNA hypermethylation in prostate cancer compared to adjacent benign tissuea
| Gene | Hypermethylated promoter CpGsb |
Evaluated promoter CpGsb |
Proportion of hypermethylated CpGs in the promoter region |
Mean β difference of promoter CpGsc |
|---|---|---|---|---|
| HES5 | 6 (6) | 8 (6) | 0.75 | 0.26 |
| TMEM106A | 6 (6) | 8 (8) | 0.75 | 0.39 |
| LOC145663 | 2 (2) | 3 (3) | 0.67 | 0.28 |
| RHCG | 6 (6) | 9 (8) | 0.67 | 0.30 |
| AOX1 | 7 (6) | 11 (9) | 0.64 | 0.32 |
| TAC1 | 7 (6) | 11 (7) | 0.64 | 0.26 |
| OXGR1 | 8 (3) | 13 (3) | 0.62 | 0.23 |
| SALL2 | 3 | 5 | 0.60 | 0.22 |
| TRIP6 | 3 | 5 | 0.60 | 0.21 |
| SCGB3A1 | 4 (4) | 7 (7) | 0.57 | 0.25 |
a
The genes in the table have more than 50% hypermethylated promoter region CpGs (Q-value <0.001).
b
The number in parenthesis represents the number of promoter region CpGs that are in a CpG island.
c
The mean β-value difference was calculated over all CpGs in the promoter region of the gene.